Published in

Public Library of Science, PLoS ONE, 10(9), p. e109759, 2014

DOI: 10.1371/journal.pone.0109759

Links

Tools

Export citation

Search in Google Scholar

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML

Journal article published in 2014 by Friederike Pastore, Greif Pa, Stephanie Schneider, Bianka Ksienzyk, Gudrun Mellert, Evelyn Zellmeier, Cristina M. Sauerland, Achim Heinecke, Sauerland Cm, Utz Krug, Jan Braess, Wolfgang Hiddemann, Bernhard Woermann, Berdel We, Philipp A. Greif ORCID and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

NPM1 mutations represent frequent genetic alterations in patients with acute myeloid leukemia (AML) associated with a favorable prognosis. Different types of NPM1 mutations have been described. The purpose of our study was to evaluate the relevance of different NPM1 mutation types with regard to clinical outcome. Our analyses were based on 349 NPM1-mutated AML patients treated in the AMLCG99 trial. Complete remission rates, overall survival and relapse-free survival were not significantly different between patients with NPM1 type A or rare type mutations. The NPM1 mutation type does not seem to play a role in risk stratification of cytogenetically normal AML.